In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
1822 News Items found
Clinical Social Worker Barbara Mitchell is seen smiling.
Talking About a Lung Cancer Diagnosis With Family, Friends, and Others

Learn how to talk about your lung cancer diagnosis with family, friends and others — including questions about smoking.
hematopoietic stem and progenitor cells
MSK Researchers Make Strides Against VEXAS Syndrome

VEXAS syndrome is a confounding adult-onset inflammatory disease first described in 2020, which affects 1 in 4,000 men over 50. Now, MSK researchers are shedding new light on its mechanisms and laying the groundwork for potential targeted treatments.
A researcher working in an MSK lab
MSK Research Highlights, October 31, 2025

New MSK research uncovers unique genetic signatures in cancer patients of non-European ancestry; identifies social adversity as a potential risk factor for higher rates of triple-negative breast cancer among Black women; shows a web-based system could help head-and-neck cancer survivors report their concerns; and finds adding immunotherapy can boost the effectiveness for hard-to-treat follicular lymphomas.
Feature
Dr. Andrew Vickers
The Truth About PSA Tests and Prostate Cancer Screening 

PSA testing is an important part of screening for prostate cancer, when it’s used the right way. Learn the truth dispelling seven myths about the PSA test.
Michael Rosensweig with dog
FDA Approves Revumenib, a Menin Inhibitor, for Aggressive Leukemia

Based on a clinical trial led by an MSK investigator, the FDA has approved revumenib (Revuforj®) for patients 1-year-old and older who have leukemia that has come back after treatment and whose cancer carries molecular changes called NPM1 mutations and KMT2A translocations.
Pattie Fuller smiles while wearing a pink plaid poncho
New Treatment for Metastatic (Stage 4) Melanoma: TIL Immunotherapy  

After immunotherapy and targeted therapy failed to bring a patient's melanoma under control, MSK doctors offered her a new treatment called tumor-infiltrating lymphocyte, or TIL, therapy.
Medical oncologist and prostate cancer specialist Dr. Wassim Abida
The Latest on Prostate Cancer Checkpoint Inhibitor Immunotherapy at MSK

Learn how genetic analysis of prostate cancer tumors is guiding treatment with checkpoint inhibitor immunotherapy.
Joey Carlsen Martinez stands smiling in front of a banner that says "Winners Circle"
New Targeted Therapy, Ulixertinib, Shows Promise for Histiocytosis, a Rare Blood Cancer 

Learn how MSK research on a family of rare blood cancers called histiocytosis is leading to new targeted therapies that benefit patients.
A close up of a microscope with two people wearing white coats in the background
ESMO 2025: MSK Presents New Research, Including Latest on Lung and Pancreatic Cancer Treatments

MSK highlights from the recent European Society for Medical Oncology (ESMO) Congress include promising findings on new lung, pancreatic, and colorectal cancer treatments and new insights for how molecular testing can guide personalized medicine.
Article
MSK breast cancer specialist Pedram Razavi, MD, PhD.
Latest Research Into Overcoming Resistance to Breast Cancer Targeted Therapies

Learn how MSK's researchers are making important strides in overcoming breast cancer resistance.